Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.
Patient, male or female, over 18 years of age
Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy
Patient with signed consent
Patients with systemic AL amyloidosis
Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
Pregnant or breastfeeding woman